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Figure S3. The 1st part of the 13C NMR spectrum of 1 (CD3OD, 125 MHz). 
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Figure S29. Two-dimensional representation of the best docking pose for compound 1 inside 
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 Figure S30. Two-dimensional representation of the best docking pose for compound 2 inside 
the topoisomerase I binding pocket. 
  
 Figure S31. Two-dimensional representation of the best docking pose for compound 3 inside 
the topoisomerase I binding pocket. 
  
 Figure S32. Two-dimensional representation of the best docking pose for compound 4 inside 
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 Figure S33. Two-dimensional representation of the best docking pose for compound 6 inside 
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 Figure S34. Two-dimensional representation of the best docking pose for compound 7 inside 
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 Figure S35. Two-dimensional representation of the best docking pose for betulinic acid inside 
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 Figure S36. Two-dimensional representation of the best docking pose for compound 1 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S37. Two-dimensional representation of the best docking pose for compound 2 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S38. Two-dimensional representation of the best docking pose for compound 3 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S39. Two-dimensional representation of the best docking pose for compound 4 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S40. Two-dimensional representation of the best docking pose for compound 6 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S41. Two-dimensional representation of the best docking pose for compound 7 inside 
the topoisomerase IIα binding pocket. 
 
  
 Figure S42. Two-dimensional representation of the best docking pose for betulinic acid inside 
the topoisomerase IIα binding pocket. 
 
 
 
 
 
 
Table S1. 
1
H and 
13
C NMR Data of Compounds 4 and 5 Recorded in CD3OD (500 MHz 
for 
1
H and 125 MHz for 
13
C) 
position 4 5 
δC δH δC δH 
1 45.6 0.95 m, 2.10 dd (12.5;4.5)a 40.3 0.98 m, 1.72 m 
2 74.2 5.05 ddd (11.0;10.0;4.5) 28.2 1.58 m, 1.62 m 
3 81.3 3.22 d (10.0) 79.6 3.14 dd (11.0;5.0) 
4 41.2 - 40.1 - 
5 56.9 0.89 m 57.2 0.76 m 
6 19.7 1.48 m, 1.57 m 19.6 1.44 m, 1.55 m 
7 35.6 1.42 m, 1.46 m 36.9 1.46 m, 1.56 m 
8 42.2 - 42.9 - 
9 52.0 1.42 m 53.6 1.37 m 
10 39.9 - 38.8 - 
11 22.4 1.30 m, 1.40 m 22.4 1.26 m, 1.51 m 
12 26.9 1.07 m, 1.72 m 26.9 0.95 m, 1.77 m 
13 39.7 2.34 bt (12.5) 40.6 2.52 td (12.5;2.5) 
14 43.8 - 47.0 - 
15 31.0 1.17 m, 1.55 m 25.4 1.45 m, 1.85 m 
16 33.6 1.40 m, 2.24 d (12.5) 34.0 1.29 m, 2.27 bd (13.0) 
17 57.7 - 57.4 - 
18 50.6 1.62 m 50.9 1.78 m 
19 48.6b 3.02 m 48.5b 3.06 m 
20 152.2 - 152.0 - 
21 31.9 1.36 m, 1.95 m 31.8 1.41 m, 1.96 m 
22 38.4 1.45 m, 1.90 m 38.1 1.44 m, 1.94 m 
23 29.2 1.04 s 28.7 0.93 s 
24 17.3 0.86 s 16.3 0.75 s 
25 17.9 1.01 s 17.3 0.90 s 
26 16.8 0.98 s 17.3 1.03 s 
27 15.2 1.02 s 64.5 4.52 d (13.0), 4.68 d (13.0) 
28 180.5 - 180.2 - 
29 110.3 4.57 bs, 4.70 bs 110.5 4.62 bs, 4.74 bs 
30 19.7 1.70 s 19.8 1.73 s 
1cc 128.0 - 127.8 - 
2c 115.3 7.04 d (2.0) 115.3 7.04 d (2.0) 
3c 147.0 - 147.0 - 
4c 149.6 - 149.9 - 
5c 116.6 6.78 d (8.0) 116.7 6.79 d (8.5) 
6c 123.0 6.94 dd (8.0;2.0) 122.8 6.95 dd (8.5;2.0) 
7c 146.7 7.55 d (16.0) 147.2 7.54 d (16.0) 
8c 116.0 6.28 d (16.0) 115.4 6.26 d (16.0) 
9c 169.5 - 169.6 - 
a
J values are given in parenthesis. b Signal overlapped with the signal of solvent; value 
 obtained from the HSQC spectrum. c “c” – caffeoyl 
 
 
Table S2. Score Values (kcal/mol) for All Studied Compounds 1–4, 6, 7 for 
Topoisomerase I Activity 
compound MolDock Score RerankScore PoseEnergy LE1 LE3 HBond 
1 -203.052 -101.365 -203,052 -350.009 -174.767 -166.501 
2 -180.151 -426.024 -180,151 -310.606 -173.452 -117.429 
3 -162.799 -125.187 -162,799 -346.382 -266.356 -142.554 
4 -171.217 -123.581 -171,217 -372.212 -268.655 -166.678 
6 -181.419 -976.498 -181,419 -394.389 -212.282 -99.534 
7 -166.217 -121.19 -166,217 -361.342 -263.456 -71.593 
BAa -125.511 -901.372 -125,511 -380.336 -253.143 -53.574 
a BA- betulinic acid 
 
Table S3. Identified Hydrogen Bonds Between Studied Ligands and Amino Acids from 
Topoisomerase I Active Site 
compound  identified hydrogen bonds between ligand and amino acids from the active site 
1 
Gly421(3.10 Ǻ), Lys374(2.85 Ǻ), Ser423(2.91 Ǻ), Lys425(3.10 Ǻ), Asp533(2.68 Ǻ), 
Ala489(3.04 Ǻ), Asn491(3.10 Ǻ) 
2 Asn491(2.48 Ǻ and 2.62 Ǻ), Val502(2.93 Ǻ), His367(2.93 Ǻ), Arg364(2.60 Ǻ and 3.10 Ǻ) 
3 Gln421 (2.74 Ǻ),  Tyr268 (2.75 Ǻ),  Gly363(2.86 Ǻ), Lys374(2.56 Ǻ and 2.84 Ǻ) 
4 Ser423(3.10 Ǻ and 3.14 Ǻ), Ser535(2.63 Ǻ and 2.81 Ǻ), His367(3.03 Ǻ) 
6 Ser719(3.22 Ǻ), Ser595(2.60 Ǻ), Arg488(3.10 Ǻ), Lys587(2.60 Ǻ) 
7 Asn491(2.56 Ǻ), Thr781(3.10 Ǻ) 
BAa Arg364(2.99 Ǻ), His367(2.88 Ǻ) 
a BA- betulinic acid 
 
Table S4. Score Values (kcal/mol) for All Studied Compounds 1–4, 6 and 7 for the 
Topoisomerase IIα Activity  
compound MolDock Score RerankScore PoseEnergy LE1 LE3 HBond 
1 -217.744 -384.338 -206.78 -375.421 -662.651 -145.673 
2 -210.952 -592.479 -204.404 -363.714 -102.152 -156.712 
3 -174.257 -118.666 -181.424 -370.759 -252.482 -180.17 
4 -182.662 -137.408 -187.287 -397.091 -298.712 -114.963 
6 -174.029 -664.934 -178.74 -378.324 -144.551 -168.656 
7 -180.373 -139.764 -185.266 -392.115 -303.834 -126.776 
BAa -129.316 -608.735 -126.593 -391.868 -184.465 -5 
a BA- betulinic acid 
 
Table S5. Identified Hydrogen Bonds Between Studied Ligands and Amino Acids from 
the Topoisomerase IIα Active Site 
compound identified hydrogen bonds between ligand and amino acids from active site 
1 Arg705(3.10 Ǻ), Glu815(2.80 Ǻ), Thr754(2.55 Ǻ and 3.10 Ǻ), Tyr735(2.78 Ǻ)  
2 Ala778(2.63 Ǻ), Lys776(3.28 Ǻ), Arg782(3.20 Ǻ) 
3 Asn757(2.86 Ǻ), Arg907(3.09 Ǻ), Gln751(3.10 Ǻ), Thr(2.94 Ǻ) 
4 Ala723(3.00 Ǻ), Glu739(2.61 Ǻ and 3.10 Ǻ) 
6 
Tyr511(3.05 Ǻ and 3.10 Ǻ), Lys776(2.79 Ǻ and 3.10 Ǻ), Ala778(3.23 Ǻ), Gln740(2.81 Ǻ), 
Ala781(2.75 Ǻ) 
7 Asn757(2.61 Ǻ), Gln704(2.59 Ǻ), Ser692(3.06 Ǻ) 
BAa Glu739(2.83 Ǻ) 
a BA- betulinic acid 
Table S6. Gradient Elution Program Used for the Silica Gel CC Separation of A. viridis 
ssp. viridis Extract  
V (mL) CH2Cl2 CH3OH fr. no. 
200 100 0 - 
800 90 10 - 
400 85 15 0-13 
400 80 20 14-34 
600 75 25 35-63 
700 70 30 64-100 
600 65 35 101-132 
400 60 40 133-155 
600 50 50 156-189 
400 40 60 190-211 
800 0 100 212-240 
 
 
